How Global Biotech Forums Are Accelerating Drug Discovery Partnerships

Executive Summary

In July 2026, Jubilant Biosys hosted the 2nd EDGE Innovation Forum in San Diego, convening more than 50 organizations—including 40 biotechnology companies, five large pharmaceutical firms, and eight investment groups—to explore pathways for accelerating next-generation therapies. The forum underscored a critical shift in drug discovery: the growing reliance on cross-sector partnerships and innovation ecosystems to bridge funding gaps, de-risk early-stage research, and speed treatments to patients.

Introduction

The biotechnology industry faces a perennial challenge: how to sustain the flow of capital and collaboration needed to translate breakthrough science into viable therapies. While scientific advances in areas such as gene editing, targeted protein degradation, and AI-driven drug design offer unprecedented potential, the path from lab to clinic remains long, costly, and fraught with uncertainty. Forums like EDGE have emerged as a vital mechanism to connect founders, investors, and pharmaceutical executives, fostering the strategic alliances that can turn promising ideas into approved medicines.

Background

Jubilant Biosys, a contract research, development, and manufacturing organization (CRDMO) based in India with operations in France and the United States, launched the EDGE Innovation Forum in 2025. The second edition, held in one of the world's leading biotech hubs—San Diego—focused on three themes: scientific innovation, capital deployment, and evolving partnership models. The event featured a startup showcase, panel discussions, and curated networking, with attendance from C-suite leaders of both emerging and established companies.

Main Analysis

The forum’s structure reflects a broader trend in the life sciences: the democratization of drug discovery. Traditionally, large pharmaceutical companies internalized most R&D. Today, however, a growing share of innovation originates from small biotech startups, academic spinouts, and virtual companies. These entities often lack the resources to advance programs beyond early-stage proof-of-concept, creating a gap commonly termed the “valley of death.”

Jubilant Biosys’s approach—combining its own scientific expertise with a platform for external collaboration—exemplifies how CRDMOs are evolving from mere service providers into ecosystem orchestrators. By hosting forums like EDGE, they facilitate the connections that can lead to licensing deals, joint ventures, or follow-on funding. The presence of more than five large pharmaceutical companies and eight investment firms at this year’s event signals a strong appetite for such matchmaking.

The startup showcase, where four biotech companies pitched their programs, is particularly significant. It offers emerging companies not only visibility but also strategic feedback and potential partnerships. This format mirrors successful models in other innovation-driven sectors, such as tech accelerators and venture capital demo days, adapted for the specific needs of life sciences.

Global Perspective

The implications of these collaborative forums extend well beyond San Diego. The global biotech landscape is increasingly interconnected, with research hubs emerging in Asia, Europe, and the Middle East. Jubilant Biosys, headquartered in India, brings a unique cross-border perspective. Indian contract research organizations have grown rapidly over the past two decades, leveraging cost advantages and a large pool of scientific talent to become integral partners in global drug development.

For the global economy, efficient drug discovery reduces healthcare costs and speeds access to treatments, benefiting patients and health systems worldwide. For innovation ecosystems, platforms like EDGE help channel capital to the most promising technologies, supporting entrepreneurship and job creation. For public policy, they highlight the need for regulatory frameworks that encourage collaboration while protecting intellectual property and ensuring patient safety.

Key Insights

• Underlying drivers: The increasing complexity of drug development and the high cost of failure are pushing the industry toward more collaborative models. No single organization can possess all the necessary capabilities, from target identification to clinical trials.
• Emerging opportunities: AI and machine learning are beginning to transform early-stage drug discovery, but these tools require large datasets and diverse expertise—exactly the kind of resources that partnerships can supply.
• Industry transformation: The rise of virtual biotechs and asset-centric companies is reshaping the competitive landscape. Large pharma increasingly relies on external innovation, while CRDMOs expand their roles as strategic partners.
• Challenges and risks: Aligning incentives, managing intellectual property, and maintaining trust across borders remain significant hurdles. Not all partnerships succeed, and the forum model must evolve to ensure sustained engagement.
• Strategic significance: Events like EDGE are not merely networking opportunities; they are becoming essential infrastructure for the modern drug discovery ecosystem, helping to de-risk investments and accelerate timelines.

Future Outlook

Over the next 5–10 years, collaborative forums are likely to proliferate and deepen. We can expect:

• AI-first partnerships: As artificial intelligence becomes central to target identification and drug design, forums will increasingly focus on data sharing and algorithm validation.
• Global expansion: CRDMOs and other orchestrators will host editions in multiple regions, reflecting the globalization of biotech hubs. Asia, particularly India and China, will play a larger role.
• Integration with venture building: Some forums may evolve into venture studios, where investors and scientists co-create startups from scratch, reducing the time from idea to company formation.
• Focus on rare diseases and global health: Funding gaps are especially acute for rare diseases and neglected tropical diseases. Collaborative platforms may prioritize these areas with dedicated tracks or challenges.
• Policy implications: Governments and international organizations may begin to support such forums as part of broader innovation strategies, given their potential to boost economic competitiveness and public health.

Conclusion

The 2nd EDGE Innovation Forum exemplifies a new paradigm in drug discovery: one where success depends on the ability to connect, collaborate, and co-create across organizational boundaries. For readers—whether business professionals, researchers, or policymakers—the key takeaway is that the future of healthcare innovation lies not in isolated breakthroughs but in the networks that nurture them. As these ecosystems mature, they hold the promise of delivering more therapies to more patients, more quickly, and more efficiently than ever before.

---

This article is based on a press release from Jubilant Biosys and incorporates additional analysis of industry trends.